Latest Breaking News On - Universidad complutense ciberonc - Page 1 : comparemela.com

The combination of durvalumab plus etoposide and cisplatin/carboplatin should now become the standard of care for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

Madrid
Spain
Geneva
Genè
Switzerland
Universidad-complutense-ciberonc
Alfredo-addeo
Luis-paz
University-hospital
Astrazeneca
Luis-paz-ares
Medical-oncology-congress